Market Access and Reimbursement Risk Assessment.

Built by former payers, HTA reviewers, and Industry Experts. 

Market Access Risk Assessment Company - MARA Rating Company

Market Access Insights

With high‑potency obesity therapies poised to reshape care

Market Access Risk Assessment MARA Rating Company

Obesity drives ≈ $173 billion in direct U.S. medical costs each year (2019 USD). Four next‑generation pipeline assets—Survodutide, Retatrutide, Orforglipron and the amylin/GLP‑1 co‑formulation Cagrilintide + Semaglutide (“CagriSema”)—promise weight‑loss efficacy on par with, or marginally beyond, today’s marketed GLP‑1s. Yet only two candidates are currently generating the breadth of comparator, durability and economic evidence that payers commonly expect.

Why Evidence Gaps Still Translate into Market‑Access Risk

Payers in major HTA jurisdictions typically look for:

  1. Direct head‑to‑head RCTs versus the locally accepted standard of care to speed appraisal.
  2. ≥ 2‑year durability & safety data, especially for chronic therapy.
  3. Early cost‑utility and budget‑impact analyses to justify prices that often exceed $10 000 per patient‑year.

At present, CagriSema is strongest across all three domains; Orforglipron is rapidly closing the gap, while Retatrutide and Survodutide remain comparator‑ and HEOR‑light.

Societal Stakes: Beyond the Price Tag

Delaying broad reimbursement perpetuates:

  • Higher chronic‑disease burden. Untreated obesity accelerates type 2 diabetes, cardiovascular disease and osteoarthritis.
  • Rising near‑term spend. Independent modelling projects a ~13 % annual social ROI from expanded anti‑obesity drug access—well below the “$6 saved for every $1 spent” often quoted, but still attractive in long‑term actuarial terms.
  • Productivity losses. Obesity‑related absenteeism alone costs U.S. employers $3.4–6.4 billion per year.
  • Equity gaps. Only a minority of Medicaid programmes and ACA plans cover GLP‑1s for obesity, concentrating access in wealthier, commercially insured groups.

MARA’s Prescription for Payer‑Ready Development

  • Benchmark early. Build Ph 2/3 protocols with active‑comparator arms and blinded extensions to ≥ 104 weeks.
  • Embed economics. Commission cost‑utility and budget‑impact models ahead of pivotal read‑outs so that HE dossiers launch in sync with clinical data.
  • Leverage external HTA frameworks. Independent appraisals surface hidden market‑access risks and reduce institutional bias.

Failure to close comparator, durability and economic gaps risks restricted indications, step‑therapy requirements and slower uptake—raising downstream costs for payers, patients and society alike.

CagriSema (Phase 2/3; MARA Rating A (Strong), 2.8 / 4)

  • Key comparative data: –17.1 % vs –9.8 % weight loss versus once-weekly semaglutide at 20 weeks (p < 0.001)
  • Durability & safety: 4.5-year REDEFINE program includes blinded extensions; cardiovascular-outcomes trial planned
  • Health-economic evidence: Sponsor has announced cost-utility and budget-impact work, but full protocols remain confidential
  • Quick read: Currently the most payer-ready package
MARA Rating A for CagriSema – strong payer-readiness across comparator, durability, and economics

Orforglipron (Phase 3; MARA Rating B++ (Marginal), 2.3 / 4)

  • Key comparative data: Superior HbA₁c and weight loss versus dulaglutide in a Phase 2 type 2 diabetes RCT
  • Durability & safety: Largest trial now reporting 40-week data; 2-year read-outs expected in 2026
  • Health-economic evidence: No published pharmacoeconomic analyses to date
  • Quick read: Comparator gap closed; durability and HEOR still maturing
MARA Rating B++ for Orforglipron – comparator gap closed, durability and HEOR still maturing

Retatrutide (Phase 2; MARA Rating B++ (Marginal), 2.4 / 4)

  • Key comparative data: Placebo + lifestyle control only; cross-trial comparisons to semaglutide and tirzepatide
  • Durability & safety: TRIUMPH-3 Phase 3 (3-year) recruiting; cardiovascular-outcomes trial planned
  • Health-economic evidence: Economic modelling not yet published
  • Quick read: Strong efficacy but no head-to-head evidence yet
MARA Rating B++ for Retatrutide – strong efficacy but awaiting head-to-head evidence

Survodutide (Phase 2; MARA Rating B+ (Very Weak), 2.2 / 4)

  • Key comparative data: Placebo-controlled obesity trial; open-label semaglutide arm only in a separate type 2 diabetes study
  • Durability & safety: Longest follow-up 46 weeks; Phase 3 safety extensions underway
  • Health-economic evidence: No peer-reviewed HEOR publications
  • Quick read: Needs active comparator and economic data for payer traction
MARA Rating B+ for Survodutide – needs active comparator and economic data

Subscribe to our newsletter for monthly HTA benchmarks: www.mararating.com 

Follow MARA Rating for independent market‑access insights: linkedin.com/company/mara‑rating‑company

#MarketAccessRiskAssessment #HTAAssessment #PricingReimbursement #ObesityTherapeutics #CagriSema #Orforglipron #Retatrutide #Survodutide Boehringer Ingelheim Novo Nordisk Eli Lilly and Company